P-157 A phase II study of XELOX and Cetuximab (Erbitux) as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (FLEET2)

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

BMC Cancer ◽

10.1186/s12885-015-1685-z ◽

2015 ◽

Vol 15 (1) ◽

Cited By ~ 12

Author(s):

Hitoshi Soda ◽

Hiromichi Maeda ◽

Junichi Hasegawa ◽

Takao Takahashi ◽

Shoichi Hazama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Multicenter Phase ◽

A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study)

Clinical Colorectal Cancer ◽

10.1016/j.clcc.2016.07.003 ◽

2016 ◽

Vol 15 (4) ◽

pp. 329-336 ◽

Cited By ~ 9

Author(s):

Shoichi Hazama ◽

Hiromichi Maeda ◽

Shigeyoshi Iwamoto ◽

Ho Min Kim ◽

Hiroyoshi Takemoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Wild Type ◽

First Line ◽

First Line Therapy ◽

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

European Journal of Cancer ◽

10.1016/s0959-8049(01)81497-0 ◽

2001 ◽

Vol 37 ◽

pp. S272 ◽

Cited By ~ 5

Author(s):

C. Twelves ◽

C. Butts ◽

J. Cassidy ◽

Th. Conroy ◽

F. DeBraud ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Preliminary Results ◽

First Line Therapy ◽

Multicenter Phase ◽

Line Therapy ◽

International Multicenter

An Open‐Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX‐6 as First‐Line Therapy for Metastatic Colorectal Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0028 ◽

2014 ◽

Vol 19 (4) ◽

pp. 350-351 ◽

Cited By ~ 37

Author(s):

Rocio Garcia‐Carbonero ◽

Fernando Rivera ◽

Joan Maurel ◽

Jean‐Pierre M. Ayoub ◽

Malcolm J. Moore ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Open Label ◽

Safety And Efficacy ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with advanced/metastatic colorectal cancer (MCRC)

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3693 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3693-3693 ◽

Cited By ~ 1

Author(s):

K. Shirao ◽

T. Doi ◽

K. Hatake ◽

Y. Arai ◽

K. Yamaguchi ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

First Line ◽

First Line Therapy ◽

Phase II Study of Bevacizumab, Capecitabine, and Oxaliplatin Followed by Bevacizumab Plus Erlotinib as First-Line Therapy in Metastatic Colorectal Cancer

Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics ◽

10.3727/096504014x13887748696743 ◽

2014 ◽

Vol 21 (4) ◽

pp. 181-191 ◽

Cited By ~ 7

Author(s):

Alberto Muñoz ◽

Carles Pericay ◽

Carlos García-Girón ◽

Vicente Alonso ◽

Rosario Dueñas ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Efficacy of aflibercept with FOLFOX and maintenance with fluoropyrimidine as first‑line therapy for metastatic colorectal cancer: GERCOR VELVET phase�II study

International Journal of Oncology ◽

10.3892/ijo.2019.4709 ◽

2019 ◽

Cited By ~ 2

Author(s):

Benoist Chibaudel ◽

Jean‑Baptiste Bachet ◽

Thierry Andr� ◽

Dominique Auby ◽

J�r�me Desram� ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group

Annals of Oncology ◽

10.1093/annonc/mdt028 ◽

2013 ◽

Vol 24 (6) ◽

pp. 1580-1587 ◽

Cited By ~ 38

Author(s):

W. Schmiegel ◽

A. Reinacher-Schick ◽

D. Arnold ◽

S. Kubicka ◽

W. Freier ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Study Group ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Randomized Phase Ii

3068 POSTER Capecitabine + irinotecan + bevacizumab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)70996-5 ◽

2007 ◽

Vol 5 (4) ◽

pp. 256-257

Author(s):

S. Beslija ◽

M. Banjin ◽

S. Jungic ◽

N. Obralic ◽

G. Kecman-Malcic ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Study Results ◽

Preliminary Phase

698 PUBLICATION Efficacy and safety findings from a phase II study of capecitabine (X) as first-line therapy in Japanese patients (pts) with metastatic colorectal cancer (MCRC): comparison with published Western data

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)80993-0 ◽

2005 ◽

Vol 3 (2) ◽

pp. 198

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Japanese Patients ◽

Efficacy And Safety ◽

First Line ◽

First Line Therapy ◽